Skip to main navigation Skip to search Skip to main content

Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study

  • Roberta Scafetta
  • , Raffaella Troiano
  • , Carla Gullotta
  • , Alessandra Guarino
  • , Cristina Fiore
  • , Luisana Sisca
  • , Elena Speziale
  • , Marco Donato
  • , Simone Foderaro
  • , Fabio Venuti
  • , Francesco Antonio Vilardi
  • , Valentina Ricozzi
  • , Michele Iuliani*
  • , Sonia Simonetti
  • , Silvia Cavaliere
  • , Alessio Cortellini
  • , Annalisa La Cesa
  • , Andrea Botticelli
  • , Simone Scagnoli
  • , Simona Pisegna
    • Carmen Criscitiello, Rebecca Pedersini, Caterina Sposetti, Elisa Tiberi, Giuliana D'Auria, Matteo Vergati, Marco Mazzotta, Roberta Caputo, Annarita Verrazzo, Ornella Garrone, Federica Domati, Claudia Piombino, Francesca Sofia Di Lisa, Lorena Filomeno, Teresa Arcuri, Federica Puce, Federica Riva, Michela Palleschi, Marianna Sirico, Marta Piras, Luigia Stefania Stucci, Delia De Lisi, Paolo Orsaria, Antonella Grasso, Edy Ippolito, Sara Ramella, Luca Visani, Lorenzo Livi, Stefania Gori, Icro Meattini, Et al.
*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Fingerprint

Dive into the research topics of 'Denosumab is associated with longer real-world progression-free survival in BRCA1/2-mutated HR+ /HER2 - breast cancer patients with bone metastases receiving CDK4/6 inhibitors: A multicenter Italian study'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

INIS

Biochemistry, Genetics and Molecular Biology

Keyphrases